Drug Profile
HL 217
Alternative Names: HL-217Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Hanlim Pharmaceutical
- Class Eye disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor inhibitors; Vascular endothelial growth factors expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Age-related macular degeneration
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Age-related-macular-degeneration(In volunteers) in France (Ophthalmic, Drops)
- 21 May 2021 Hanlim Pharmaceutical completes a phase II trial in Age-related macular degeneration (In adults, In the elderly) in Bulgaria and France (Ophthalmic) (EudraCT2019-000642-35)
- 28 Mar 2020 No recent reports of development identified for phase-I development in Age-related-macular-degeneration(In volunteers) in Unknown (Ophthalmic, Drops)